Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18583904 | 0.84 | L3MBTL1 (0.35) | CA12CA2CA9RAB9AALDH1A1 | |
| SCHEMBL21276638 | 0.84 | CA12 (0.33) | CA12CA2CA9RAB9AALDH1A1 | |
| SCHEMBL14024554 | 0.84 | L3MBTL1 (0.35) | CA12CA2CA9RAB9AALDH1A1 | |
| SCHEMBL19718545 | 0.82 | CA12 (0.32) | CA12CA2CA9RAB9A | |
| SCHEMBL22481904 | 0.81 | CA12 (0.32) | CA12CA2CA9RAB9A | |
| SCHEMBL14427457 | 0.80 | CA12 (0.31) | CA12CA2CA9TRPA1 | |
| SCHEMBL11986402 | 0.79 | CA12 (0.39) | CA12CA2CA9RAB9AALDH1A1 | |
| SCHEMBL2340381 | 0.77 | LMNA (0.38) | RAB9AALDH1A1KDM4EMAPTTRPA1 | |
| SCHEMBL20216019 | 0.76 | RECQL (0.41) | RAB9AALDH1A1KDM4EPOLBMAPT | |
| SCHEMBL20747503 | 0.75 | MAPT (0.39) | RAB9AALDH1A1L3MBTL1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292178-A9 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292178-A9 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL26, RPL35, RPL5 | CA12 3585/4885CA2 4703/4885CA9 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.